- Conditions
- Thyroid Eye Disease
- Interventions
- Teprotumumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 3
- States / cities
- Miami, Florida • St Louis, Missouri • Bellaire, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 601–624
of 807
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
- Interventions
- ADVM-022
- Biological
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 11
- States / cities
- Bakersfield, California • Beverly Hills, California • Golden, Colorado + 8 more
- Conditions
- Retinal Hemangioblastoma, Von Hippel-Lindau Disease
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 7 Years to 120 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Thyroid Eye Disease, Chronic (Inactive) Thyroid Eye Disease
- Interventions
- TEPEZZA, Placebo
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 12
- States / cities
- Beverly Hills, California • La Jolla, California • Los Angeles, California + 9 more
- Conditions
- ROSAH
- Interventions
- DF-003
- Drug
- Lead sponsor
- Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Bethesda, Maryland • Durham, North Carolina • Salt Lake City, Utah
- Conditions
- Down Syndrome (DS), Keratoconus, Pellucid Marginal Degeneration, Forme Fruste Keratoconus (FFK)
- Interventions
- Epi-ON corneal cross-linking (CXL)
- Combination Product
- Lead sponsor
- Woolfson Eye Institute
- Other
- Eligibility
- 8 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 12
- States / cities
- Atlanta, Georgia • Canton, Georgia • Cumming, Georgia + 8 more
- Conditions
- Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Blindness
- Interventions
- Supplemental Oxygen Management, Conventional Oxygen Management
- Procedure
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- Up to 48 Hours
- Enrollment
- 649 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 1999
- U.S. locations
- 9
- States / cities
- Palo Alto, California • New Haven, Connecticut • Atlanta, Georgia + 6 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Brolucizumab, Aflibercept
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 535 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 60
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Huntington Beach, California + 51 more
- Conditions
- Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Bronchopulmonary Dysplasia (BPD)
- Interventions
- Inositol lower volume, Inositol mid-level volume, Inositol high volume, Placebo low volume
- Drug
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- 12 Hours to 72 Hours
- Enrollment
- 125 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more
- Conditions
- Cataract, Down Syndrome
- Interventions
- cataract surgery
- Procedure
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 1 Month to 18 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Keratoconus, Corneal Opacity, Corneal Dystrophy
- Interventions
- Optical Coherence Tomography
- Device
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 14 Years to 85 Years
- Enrollment
- 445 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2031
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Retinoblastoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- alvocidib, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Arcadia, California
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- AKST4290, Placebo, Aflibercept
- Drug
- Lead sponsor
- Alkahest, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • St. Petersburg, Florida • Reno, Nevada
- Conditions
- Cytomegalovirus Retinitis, HIV Infections, Gastrointestinal Diseases
- Interventions
- Ganciclovir
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1995
- U.S. locations
- 17
- States / cities
- San Francisco, California • Denver, Colorado • Wilmington, Delaware + 12 more
- Conditions
- Hermansky-Pudlak Syndrome (HPS), Pulmonary Fibrosis, Oculocutaneous Albinism, Platelet Storage Pool Deficiency, Metabolic Disease
- Interventions
- Losartan, Zileuton, N-Acetylcysteine, Pravastatin, Erythromycin
- Drug
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Fuchs' Endothelial Dystrophy
- Interventions
- DSAEK with graft shaping and smoothing, Standard DSAEK
- Procedure
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Retinopathy of Prematurity (ROP)
- Interventions
- 1% phenylephrine and 0.2% cyclopentolate
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- Not listed
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Retinal Detachment, Epiretinal Membrane, Macular Hole, Fuchs Endothelial Dystrophy
- Interventions
- Not listed
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Retinoblastoma
- Interventions
- subtenon Carboplatin, Topotecan Hydrochloride, Vincristine, Filgrastim
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Up to 10 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Normal Eyes, Eye Abnormalities
- Interventions
- BI Anterior Segment Mode, BI Anterior Segment and IOL Biometry Mode
- Device
- Lead sponsor
- Heidelberg Engineering GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chediak-Higashi Syndrome, Graft Versus Host Disease, X-Linked Lymphoproliferative Syndrome, Familial Erythrophagocytic Lymphohistiocytosis, Hemophagocytic Lymphohistiocytosis, Virus-Associated Hemophagocytic Syndrome
- Interventions
- anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, etoposide, filgrastim, methotrexate, allogeneic hematopoietic stem cell transplantation
- Drug · Procedure
- Lead sponsor
- Fairview University Medical Center
- Other
- Eligibility
- 0 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Apnea of Prematurity, Retinopathy of Prematurity, Pain
- Interventions
- sucrose solution
- Dietary Supplement
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 5 Weeks and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Retinitis Pigmentosa, Leber Congenital Amaurosis
- Interventions
- OCU400 Low Dose, OCU400 Med Dose, OCU400 High Dose, OCU400 Second Eye Dosing
- Drug
- Lead sponsor
- Ocugen
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • La Jolla, California • Miami, Florida + 4 more
- Conditions
- Bowel; Stricture
- Interventions
- GIE Medical ProTractX3 TTS DCB, Control
- Combination Product · Other
- Lead sponsor
- GIE Medical
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 32
- States / cities
- Scottsdale, Arizona • Irvine, California • Lancaster, California + 25 more